Molecular.roche.com
For Patients
For Labs
Screening Portfolio
Contact
  • roche logo
CERVICAL CANCER SCREENING
COBAS® HPV TEST
ATHENA HPV CLINICAL TRIAL
CLINICAL GUIDELINES
HPV NEWS & RESOURCES
Molecular.roche.com
For Patients
For Labs
Screening Portfolio
Contact
 Share your feedback 

The cobas® HPV Test: 3 hrHPV results in one test for confident risk stratification1

cobas® HPV Test 3 in 1

The detail to make decisions based upon your patient’s real risk

Trust cobas® HPV Test, a clinically validated FDA-approved and CE-marked assay that identifies high-risk HPV with simultaneous individual genotyping of the most oncogenic HPV16 and HPV18.

The cobas® HPV Test has the potential to set a new standard of testing:

  • Significantly enhances risk stratification
  • Lets you focus on the few women who need aggressive treatment
  • Lets you reassure the vast majority of women that they are at very low risk

Confidence with the cobas® HPV Test

Precise results you can trust

The cobas® HPV Test offers:

  • No cross-reactivity with low-risk HPV types
  • Results are positive, negative, or invalid with no gray zone
  • Reproducible results with real-time PCR
     

Reduced false negatives1

  • ß-globin internal control for sample adequacy
     

Reduced false positives1

  • External control
  • No cross-reactivity with low-risk HPV genotypes
     

For additional technical specifications on the cobas® HPV Test, visit molecular.roche.com

  • Acronyms:

References:

1. cobas® 4800 HPV Test US package insert. April 2011.
09/30/2019

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.